NASDAQ:AKBA - Akebia Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$10.30 -0.06 (-0.58 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$10.30
Today's Range$10.26 - $10.50
52-Week Range$8.93 - $20.25
Volume176,695 shs
Average Volume415,764 shs
Market Capitalization$588.74 million
P/E Ratio-5.82
Dividend YieldN/A
Beta1.09

About Akebia Therapeutics (NASDAQ:AKBA)

Akebia Therapeutics logoAkebia Therapeutics, Inc. is a biopharmaceutical company which engages in the development of novel proprietary therapeutics based on hypoxia-inducible factor and biology. It also includes the development and commercialization of drugs for the treatment of renal and metabolic disorders. It offers vadadustat which is an oral therapy in a phase three development that has the potential to set a new standard of care in treatment of anemia associated with chronic kidney disease. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Receive AKBA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKBA
CUSIPN/A
Phone617-871-2098

Debt

Debt-to-Equity RatioN/A
Current Ratio2.89
Quick Ratio2.89

Price-To-Earnings

Trailing P/E Ratio-5.82
Forward P/E Ratio-4.93
P/E GrowthN/A

Sales & Book Value

Annual Sales$177.98 million
Price / Sales3.29
Cash FlowN/A
Price / CashN/A
Book Value$3.46 per share
Price / Book2.98

Profitability

EPS (Most Recent Fiscal Year)($1.77)
Net Income$-76,910,000.00
Net Margins-27.48%
Return on Equity-47.15%
Return on Assets-15.05%

Miscellaneous

Employees114
Outstanding Shares56,880,000

Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics Inc. (NASDAQ:AKBA) released its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.01. The biopharmaceutical company had revenue of $45.93 million for the quarter, compared to the consensus estimate of $47.80 million. Akebia Therapeutics had a negative return on equity of 47.15% and a negative net margin of 27.48%. View Akebia Therapeutics' Earnings History.

When is Akebia Therapeutics' next earnings date?

Akebia Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Akebia Therapeutics.

What price target have analysts set for AKBA?

6 Wall Street analysts have issued 1-year price objectives for Akebia Therapeutics' stock. Their forecasts range from $17.00 to $30.00. On average, they anticipate Akebia Therapeutics' share price to reach $24.20 in the next year. View Analyst Ratings for Akebia Therapeutics.

What are Wall Street analysts saying about Akebia Therapeutics stock?

Here are some recent quotes from research analysts about Akebia Therapeutics stock:
  • 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (5/14/2018)
  • 2. Mizuho analysts commented, "We had a chance to catch up with CEO John Butler yesterday at the Bio CEO & Investor Conference. We summarize our key takeaways below. Akebia also provided an update on the Vadadustat development program yesterday morning including an expansion of the ongoing phase 2 For2ward and phase 3 Trilo2gy trials in collaboration with Otsuka (TYO:4578, Non rated). While this will delay the timeline for topline data in both programs, we see it as a positive overall as the company will now incorporate additional relevant endpoints with a greater number of patients for better positioning in commercialization. The timeline for data-readouts in the two pivotal Pro2tect and Inno2vate trials remains unchanged." (2/13/2018)

Who are some of Akebia Therapeutics' key competitors?

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the folowing people:
  • John P. Butler, President, CEO & Director
  • Gavin T. Malenfant, Vice President-Operations
  • Jason A. Amello, CFO, Treasure, SVP & Principal Accounting Officer
  • Rita Jain, Chief Medical Officer & Senior Vice President
  • Michel Dahan, Chief Business Officer & Senior Vice President

Has Akebia Therapeutics been receiving favorable news coverage?

Press coverage about AKBA stock has trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Akebia Therapeutics earned a media sentiment score of 0.16 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.82 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.56%), Eagle Asset Management Inc. (4.79%), Millennium Management LLC (1.16%), DAFNA Capital Management LLC (1.07%), Northern Trust Corp (0.91%) and American Century Companies Inc. (0.88%). Company insiders that own Akebia Therapeutics stock include Duane Nash, Michel Dahan, Muneer A Satter and Nicole R Hadas. View Institutional Ownership Trends for Akebia Therapeutics.

Which institutional investors are selling Akebia Therapeutics stock?

AKBA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Wells Fargo & Company MN and Citigroup Inc.. Company insiders that have sold Akebia Therapeutics company stock in the last year include Duane Nash, Michel Dahan and Nicole R Hadas. View Insider Buying and Selling for Akebia Therapeutics.

Which institutional investors are buying Akebia Therapeutics stock?

AKBA stock was purchased by a variety of institutional investors in the last quarter, including Artal Group S.A., DAFNA Capital Management LLC, BlackRock Inc., CVI Holdings LLC, Stanley Laman Group Ltd., PNC Financial Services Group Inc., Point72 Asset Management L.P. and Spark Investment Management LLC. View Insider Buying and Selling for Akebia Therapeutics.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $10.30.

How big of a company is Akebia Therapeutics?

Akebia Therapeutics has a market capitalization of $588.74 million and generates $177.98 million in revenue each year. The biopharmaceutical company earns $-76,910,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Akebia Therapeutics employs 114 workers across the globe.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]


MarketBeat Community Rating for Akebia Therapeutics (AKBA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  243 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  395
MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe AKBA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKBA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Akebia Therapeutics (NASDAQ:AKBA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Akebia Therapeutics in the last 12 months. Their average twelve-month price target is $24.20, suggesting that the stock has a possible upside of 134.95%. The high price target for AKBA is $30.00 and the low price target for AKBA is $17.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.892.892.86
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.20$22.7778$22.7778$21.2857
Price Target Upside: 134.95% upside68.47% upside57.63% upside49.48% upside

Akebia Therapeutics (NASDAQ:AKBA) Consensus Price Target History

Price Target History for Akebia Therapeutics (NASDAQ:AKBA)

Akebia Therapeutics (NASDAQ:AKBA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018MizuhoReiterated RatingBuy$24.00LowView Rating Details
12/18/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$26.00MediumView Rating Details
12/7/2017BTIG ResearchInitiated CoverageBuy ➝ Buy$30.00MediumView Rating Details
11/15/2017HC WainwrightReiterated RatingBuy$24.00N/AView Rating Details
11/2/2017Royal Bank of CanadaReiterated RatingHold$17.00N/AView Rating Details
6/30/2017AegisReiterated RatingBuyHighView Rating Details
5/17/2017Needham & Company LLCReiterated RatingBuy$18.00 ➝ $21.00LowView Rating Details
5/5/2017UBSReiterated RatingBuy$12.00 ➝ $17.00N/AView Rating Details
4/26/2017JMP SecuritiesBoost Price TargetOutperform$19.00 ➝ $21.00HighView Rating Details
9/29/2016Brean CapitalInitiated CoverageBuy$18.00N/AView Rating Details
8/9/2016Credit Suisse GroupReiterated RatingHold$8.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Akebia Therapeutics (NASDAQ:AKBA) Earnings History and Estimates Chart

Earnings by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Akebia Therapeutics (NASDAQ:AKBA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.51)
2019 EPS Consensus Estimate: ($2.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.47)($0.47)($0.47)
Q3 20181($0.49)($0.49)($0.49)
Q4 20181($0.55)($0.55)($0.55)
Q1 20191($0.56)($0.56)($0.56)
Q2 20191($0.62)($0.62)($0.62)
Q3 20191($0.55)($0.55)($0.55)
Q4 20191($0.27)($0.27)($0.27)

Akebia Therapeutics (NASDAQ AKBA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.50)N/AView Earnings Details
5/9/2018Q1 2018($0.49)($0.48)$47.80 million$45.93 millionViewN/AView Earnings Details
3/12/2018Q4 2017($0.36)$0.25$66.00 million$87.32 millionViewListenView Earnings Details
11/8/2017Q3 2017($0.56)($0.49)$34.00 million$41.28 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.89)($0.53)$26.50 million$28.52 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.15)($1.15)$16.50 million$20.87 millionViewN/AView Earnings Details
3/6/2017Q4 2016$0.77($0.99)$125.00 million$1.54 millionViewListenView Earnings Details
11/9/2016Q3($1.09)($0.96)ViewN/AView Earnings Details
8/8/2016Q2 2016($0.57)($0.95)$6.00 millionViewN/AView Earnings Details
5/5/2016Q1 2016($0.43)($0.70)$9.00 millionViewN/AView Earnings Details
3/14/2016Q415($0.28)($0.66)$11.60 millionViewListenView Earnings Details
11/9/2015Q3($0.52)($0.68)ViewN/AView Earnings Details
8/11/2015Q215($0.51)($0.40)ViewN/AView Earnings Details
5/11/2015Q1 2015($0.57)($0.53)ViewN/AView Earnings Details
3/4/2015Q414($0.66)($0.52)ViewN/AView Earnings Details
11/10/2014Q314($0.45)($0.47)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.34)($0.39)ViewN/AView Earnings Details
5/12/2014Q1 2014($43.37)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Akebia Therapeutics (NASDAQ:AKBA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Akebia Therapeutics (NASDAQ AKBA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.95%
Institutional Ownership Percentage: 75.66%
Insider Trading History for Akebia Therapeutics (NASDAQ:AKBA)
Institutional Ownership by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Akebia Therapeutics (NASDAQ AKBA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2018Duane NashDirectorSell1,000$14.62$14,620.00View SEC Filing  
10/2/2017Duane NashDirectorSell1,188$19.64$23,332.32View SEC Filing  
10/2/2017Michel DahanSVPSell1,398$19.64$27,456.72View SEC Filing  
9/28/2017Michel DahanSVPSell5,000$19.30$96,500.0097,224View SEC Filing  
8/15/2017Michel DahanSVPSell5,000$15.00$75,000.00102,224View SEC Filing  
7/5/2017Muneer A SatterDirectorBuy1,034,482$14.50$14,999,989.00View SEC Filing  
7/3/2017Duane NashDirectorSell990$14.27$14,127.3023,687View SEC Filing  
7/3/2017Nicole R. HadasSVPSell1,554$14.26$22,160.04View SEC Filing  
4/3/2017Duane NashDirectorSell991$9.20$9,117.2024,677View SEC Filing  
4/3/2017Nicole R HadasSVPSell1,556$9.18$14,284.08109,856View SEC Filing  
1/3/2017Duane NashDirectorSell1,980$10.46$20,710.8025,668View SEC Filing  
1/1/2017Nicole R. HadasSVPSell1,810$10.49$18,986.90View SEC Filing  
7/6/2016Duane NashDirectorSell1,980$7.48$14,810.4029,629View SEC Filing  
7/5/2016Nicole R. HadasSVPSell1,557$7.47$11,630.79View SEC Filing  
4/4/2016Michel DahanSVPSell1,401$9.41$13,183.4174,956View SEC Filing  
10/2/2015Nicole R HadasSVPSell1,484$8.67$12,866.2865,260View SEC Filing  
7/2/2015Nicole R HadasSVPSell1,484$9.54$14,157.36View SEC Filing  
4/22/2015Muneer A SatterDirectorBuy420,000$8.25$3,465,000.00View SEC Filing  
4/2/2015Nicole R HadasSVPSell1,483$9.09$13,480.47View SEC Filing  
1/2/2015Nicole R HadasVPSell1,715$11.46$19,653.90View SEC Filing  
12/29/2014John P ButlerCEOBuy1,000$11.57$11,570.00View SEC Filing  
12/26/2014Duane NashDirectorSell11,933$11.23$134,007.59View SEC Filing  
12/22/2014John P ButlerCEOBuy1,000$11.92$11,920.00View SEC Filing  
12/15/2014John P ButlerCEOBuy1,000$11.34$11,340.00View SEC Filing  
12/2/2014Ronald C Renaud JrDirectorBuy5,000$11.92$59,600.00View SEC Filing  
11/26/2014Jason AmelloCFOBuy1,000$13.22$13,220.00View SEC Filing  
11/25/2014Muneer A SatterDirectorBuy5,000$13.18$65,900.00View SEC Filing  
11/24/2014Muneer A SatterDirectorBuy5,000$13.88$69,400.00View SEC Filing  
11/21/2014Muneer A SatterDirectorBuy5,000$14.73$73,650.00View SEC Filing  
11/20/2014Muneer A SatterDirectorBuy5,000$14.70$73,500.00View SEC Filing  
11/19/2014Muneer A SatterDirectorBuy5,000$14.85$74,250.00View SEC Filing  
11/18/2014Muneer A SatterDirectorBuy5,000$13.84$69,200.00View SEC Filing  
11/17/2014Muneer A SatterDirectorBuy5,000$12.94$64,700.00View SEC Filing  
11/14/2014Muneer A SatterDirectorBuy5,000$11.91$59,550.00View SEC Filing  
11/13/2014Muneer A SatterDirectorBuy5,000$11.56$57,800.00View SEC Filing  
11/12/2014John P ButlerCEOBuy1,000$10.31$10,310.00View SEC Filing  
11/12/2014Muneer A SatterDirectorBuy5,000$11.90$59,500.00View SEC Filing  
3/25/2014A/S NovoInsiderBuy182,590$17.00$3,104,030.00View SEC Filing  
3/25/2014Jason AmelloCFOBuy4,000$17.00$68,000.00View SEC Filing  
3/25/2014John P ButlerCEOBuy13,850$17.00$235,450.00View SEC Filing  
3/25/2014Muneer A SatterDirectorBuy91,295$17.00$1,552,015.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Akebia Therapeutics (NASDAQ AKBA) News Headlines

Source:
DateHeadline
Zacks: Brokerages Anticipate Akebia Therapeutics Inc. (AKBA) Will Announce Quarterly Sales of $48.75 MillionZacks: Brokerages Anticipate Akebia Therapeutics Inc. (AKBA) Will Announce Quarterly Sales of $48.75 Million
www.americanbankingnews.com - May 18 at 5:59 AM
Akebia Therapeutics Inc. (AKBA) Expected to Post Earnings of -$0.52 Per ShareAkebia Therapeutics Inc. (AKBA) Expected to Post Earnings of -$0.52 Per Share
www.americanbankingnews.com - May 16 at 3:14 AM
Akebia Therapeutics to Present at Upcoming Investor ConferenceAkebia Therapeutics to Present at Upcoming Investor Conference
finance.yahoo.com - May 15 at 5:23 PM
Akebia Therapeutics (AKBA) Rating Increased to Hold at Zacks Investment ResearchAkebia Therapeutics (AKBA) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - May 14 at 4:27 PM
Q2 2018 EPS Estimates for Akebia Therapeutics Inc. (AKBA) Increased by AnalystQ2 2018 EPS Estimates for Akebia Therapeutics Inc. (AKBA) Increased by Analyst
www.americanbankingnews.com - May 14 at 2:50 AM
Akebia Therapeutics Inc. Expected to Post FY2021 Earnings of $0.80 Per Share (AKBA)Akebia Therapeutics Inc. Expected to Post FY2021 Earnings of $0.80 Per Share (AKBA)
www.americanbankingnews.com - May 11 at 11:46 AM
Akebia Therapeutics (AKBA) Issues  Earnings Results, Beats Expectations By $0.01 EPSAkebia Therapeutics (AKBA) Issues Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 10 at 6:12 PM
Akebia Therapeutics (AKBA) Earns Buy Rating from MizuhoAkebia Therapeutics (AKBA) Earns Buy Rating from Mizuho
www.americanbankingnews.com - May 10 at 11:03 AM
Akebia Therapeutics: 1Q Earnings SnapshotAkebia Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 8:57 AM
Akebia Therapeutics Announces First Quarter 2018 Financial ResultsAkebia Therapeutics Announces First Quarter 2018 Financial Results
www.bizjournals.com - May 9 at 5:05 PM
Akebia Therapeutics Inc. (AKBA) Receives Consensus Recommendation of "Hold" from BrokeragesAkebia Therapeutics Inc. (AKBA) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 6 at 10:19 AM
Akebia Therapeutics (AKBA) and ImmunoGen (IMGN) Critical ReviewAkebia Therapeutics (AKBA) and ImmunoGen (IMGN) Critical Review
www.americanbankingnews.com - May 2 at 10:00 PM
Akebia Therapeutics (AKBA) Scheduled to Post Earnings on MondayAkebia Therapeutics (AKBA) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - April 30 at 9:22 AM
Zacks: Brokerages Anticipate Akebia Therapeutics Inc. (AKBA) Will Post Quarterly Sales of $47.80 MillionZacks: Brokerages Anticipate Akebia Therapeutics Inc. (AKBA) Will Post Quarterly Sales of $47.80 Million
www.americanbankingnews.com - April 30 at 2:58 AM
Akebia Therapeutics Inc. (AKBA) Expected to Post Earnings of -$0.55 Per ShareAkebia Therapeutics Inc. (AKBA) Expected to Post Earnings of -$0.55 Per Share
www.americanbankingnews.com - April 28 at 3:14 PM
Akebia Therapeutics (AKBA) Cut to Strong Sell at ValuEngineAkebia Therapeutics (AKBA) Cut to Strong Sell at ValuEngine
www.americanbankingnews.com - April 27 at 1:59 PM
Akebia Therapeutics (AKBA) Upgraded to "Hold" at Zacks Investment ResearchAkebia Therapeutics (AKBA) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 23 at 4:04 PM
Akebia Therapeutics Inc. (AKBA) Expected to Post Quarterly Sales of $49.65 MillionAkebia Therapeutics Inc. (AKBA) Expected to Post Quarterly Sales of $49.65 Million
www.americanbankingnews.com - April 13 at 2:35 AM
Akebia Therapeutics Inc. (AKBA) Expected to Announce Earnings of -$0.68 Per ShareAkebia Therapeutics Inc. (AKBA) Expected to Announce Earnings of -$0.68 Per Share
www.americanbankingnews.com - April 11 at 3:10 PM
Akebia Therapeutics Inc. (AKBA) Given Average Recommendation of "Buy" by BrokeragesAkebia Therapeutics Inc. (AKBA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 11 at 8:39 AM
Akebia (AKBA) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowAkebia (AKBA) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 10 at 5:03 PM
Akebia Therapeutics (AKBA) Rating Increased to Hold at ValuEngineAkebia Therapeutics (AKBA) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - April 3 at 8:11 PM
Stock Traders Buy Large Volume of Call Options on Akebia Therapeutics (AKBA)Stock Traders Buy Large Volume of Call Options on Akebia Therapeutics (AKBA)
www.americanbankingnews.com - April 3 at 7:40 AM
Akebia Therapeutics (AKBA) Buy Rating Reiterated at MizuhoAkebia Therapeutics' (AKBA) Buy Rating Reiterated at Mizuho
www.americanbankingnews.com - March 31 at 5:28 PM
Akebia Therapeutics Announces Pricing of Public Offering of Common StockAkebia Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - March 31 at 8:46 AM
Q2 2018 EPS Estimates for Akebia Therapeutics Inc (AKBA) Increased by AnalystQ2 2018 EPS Estimates for Akebia Therapeutics Inc (AKBA) Increased by Analyst
www.americanbankingnews.com - March 28 at 7:04 AM
Piper Jaffray Weighs in on Akebia Therapeutics Incs FY2020 Earnings (AKBA)Piper Jaffray Weighs in on Akebia Therapeutics Inc's FY2020 Earnings (AKBA)
www.americanbankingnews.com - March 27 at 7:52 AM
Akebia Therapeutics (AKBA) Prices 8.5M Common Stock Offering at $10.50/ShareAkebia Therapeutics (AKBA) Prices 8.5M Common Stock Offering at $10.50/Share
www.streetinsider.com - March 26 at 9:04 AM
Akebia Therapeutics down 11% on pricing public offering of common stockAkebia Therapeutics down 11% on pricing public offering of common stock
seekingalpha.com - March 24 at 4:54 PM
Akebia Therapeutics Announces Proposed Public Offering of Common StockAkebia Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 22 at 5:08 PM
Akebia Therapeutics to Present at Upcoming Investor Conferences - Business Wire (press release)Akebia Therapeutics to Present at Upcoming Investor Conferences - Business Wire (press release)
www.businesswire.com - March 21 at 9:43 AM
Akebia Therapeutics to Present at Upcoming Investor ConferencesAkebia Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - March 21 at 9:43 AM
Blog Exposure - Chiasma to Present Design of Phase-3 Double-Blind Trial of Oral Octreotide Capsules Versus Placebo in Acromegaly Patients at ENDO 2018Blog Exposure - Chiasma to Present Design of Phase-3 Double-Blind Trial of Oral Octreotide Capsules Versus Placebo in Acromegaly Patients at ENDO 2018
finance.yahoo.com - March 20 at 9:03 AM
Akebia Therapeutics (AKBA) Stock Rating Reaffirmed by MizuhoAkebia Therapeutics (AKBA) Stock Rating Reaffirmed by Mizuho
www.americanbankingnews.com - March 18 at 2:45 PM
Akebia Therapeutics (AKBA) Downgraded by BidaskClubAkebia Therapeutics (AKBA) Downgraded by BidaskClub
www.americanbankingnews.com - March 17 at 7:48 PM
Akebia Therapeutics Inc (AKBA) Given Consensus Rating of "Hold" by BrokeragesAkebia Therapeutics Inc (AKBA) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 17 at 7:30 AM
Akebia Therapeutics (AKBA) Rating Lowered to Sell at Zacks Investment ResearchAkebia Therapeutics (AKBA) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 15 at 4:20 PM
Akebia Therapeutics (AKBA) Cut to Sell at ValuEngineAkebia Therapeutics (AKBA) Cut to Sell at ValuEngine
www.americanbankingnews.com - March 13 at 11:28 PM
Akebia Therapeutics (AKBA) Issues Quarterly  Earnings Results, Beats Estimates By $0.61 EPSAkebia Therapeutics (AKBA) Issues Quarterly Earnings Results, Beats Estimates By $0.61 EPS
www.americanbankingnews.com - March 13 at 8:12 AM
Akebia Therapeutics, Inc. to Host Earnings CallAkebia Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 12 at 6:07 PM
Akebia Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial ResultsAkebia Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - March 12 at 6:07 PM
Akebia Therapeutics posts 4Q profitAkebia Therapeutics posts 4Q profit
finance.yahoo.com - March 12 at 6:07 PM
Akebia Therapeutics (AKBA) Given a $24.00 Price Target at MizuhoAkebia Therapeutics (AKBA) Given a $24.00 Price Target at Mizuho
www.americanbankingnews.com - March 7 at 7:30 PM
Contrasting Akebia Therapeutics (AKBA) and Progenics Pharmaceuticals (PGNX)Contrasting Akebia Therapeutics (AKBA) and Progenics Pharmaceuticals (PGNX)
www.americanbankingnews.com - March 7 at 1:16 AM
Akebia Therapeutics to Host Fourth Quarter and Full-Year 2017 Investor Update Call and WebcastAkebia Therapeutics to Host Fourth Quarter and Full-Year 2017 Investor Update Call and Webcast
finance.yahoo.com - March 5 at 8:51 AM
Akebia Therapeutics (AKBA) Upgraded at ValuEngineAkebia Therapeutics (AKBA) Upgraded at ValuEngine
www.americanbankingnews.com - March 5 at 12:48 AM
Spark Investment Management LLC Purchases 84,600 Shares of Akebia Therapeutics Inc (AKBA)Spark Investment Management LLC Purchases 84,600 Shares of Akebia Therapeutics Inc (AKBA)
www.americanbankingnews.com - March 2 at 9:00 PM
Akebia Therapeutics (AKBA) Scheduled to Post Quarterly Earnings on WednesdayAkebia Therapeutics (AKBA) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:24 AM
Carillon Tower Advisers Inc. Buys Shares of 2,060,804 Akebia Therapeutics Inc (AKBA)Carillon Tower Advisers Inc. Buys Shares of 2,060,804 Akebia Therapeutics Inc (AKBA)
www.americanbankingnews.com - February 27 at 5:32 AM
Akebia Therapeutics (AKBA) Lowered to Sell at BidaskClubAkebia Therapeutics (AKBA) Lowered to Sell at BidaskClub
www.americanbankingnews.com - February 25 at 6:35 PM

SEC Filings

Akebia Therapeutics (NASDAQ:AKBA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Akebia Therapeutics (NASDAQ:AKBA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Akebia Therapeutics (NASDAQ AKBA) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.